| 000 | 01336 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250517082624.0 | ||
| 264 | 0 | _c20161213 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a1534-6269 | ||
| 024 | 7 |
_a10.1007/s11912-016-0509-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFriedman, Claire F | |
| 245 | 0 | 0 |
_aEmerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. _h[electronic resource] |
| 260 |
_bCurrent oncology reports _cApr 2016 |
||
| 300 |
_a21 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntibodies _ximmunology |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xblood |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xblood |
| 650 | 0 | 4 |
_aCTLA-4 Antigen _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 | _aIpilimumab |
| 650 | 0 | 4 |
_aMelanoma _xblood |
| 650 | 0 | 4 | _aNivolumab |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xblood |
| 650 | 0 | 4 |
_aTumor Microenvironment _ximmunology |
| 700 | 1 | _aPostow, Michael A | |
| 773 | 0 |
_tCurrent oncology reports _gvol. 18 _gno. 4 _gp. 21 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11912-016-0509-x _zAvailable from publisher's website |
| 999 |
_c25776318 _d25776318 |
||